A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Trial Profile

A Clinical Study to Demonstrate Safety and Efficacy of E7777 in Persistent or Recurrent Cutaneous T-Cell Lymphoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs Denileukin diftitox (Primary)
  • Indications Cutaneous T cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 10 Aug 2016 Planned number of patients changed from 21 to 90.
    • 10 Aug 2016 Planned End Date changed from 1 Nov 2016 to 1 Jun 2019.
    • 10 Aug 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top